AFFiRiS is a pioneering brand that is committed to improving the lives of patients suffering from chronic diseases. Founded in 2003, their vision is to harness the power of the immune system to identify and combat proteins that play a central role in the development and progression of chronic human diseases. Unlike traditional approaches that merely manage symptoms, AFFiRiS focuses on targeting the root cause of these diseases.

Their range of products and services includes innovative immunotherapies that have shown promising results in clinical trials. Currently, their lead candidate is being investigated for the treatment of hypercholesterolemia. Backed by a talented team of dedicated professionals, AFFiRiS has a proven track record of groundbreaking scientific discoveries and the development of novel therapies.

With their expertise and commitment, they aim to make a significant impact in the field of chronic disease treatment. AFFiRiS is also actively involved in collaborations with renowned institutions and industry partners to further advance their research and development efforts. Furthermore, they provide opportunities for collaboration with external parties and welcome investors who share their vision and mission.

Headquartered in Vienna, Austria, AFFiRiS is at the forefront of cutting-edge immunotherapy, offering hope to countless patients worldwide